Statins Induce the Regression of Left Ventricular Mass in Patients with Angina

Circulation Journal

Volumn 68, Issue 2, 2004, Pages 121-125

  Nishikawa, Hiroaki ^a   Miura, Shin Ichiro ^a   Zhang, Bo ^a   Shimomura, Hideki ^b   Arai, Hidekazu ^b   Tsuchiya, Yoshihiro ^a   Matsuo, Kunihiro ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Fukuoka Tokusyukai Hospital   (Japan)

Author keywords

Echocardiography; Left ventricular mass index; Statins

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE DINITRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME;

AGED; ANGINA PECTORIS; CALCIUM CHANNEL BLOCKERS; CARDIOMEGALY; CASE-CONTROL STUDIES; CONSTRICTION, PATHOLOGIC; DRUG EVALUATION; FEMALE; HEART VENTRICLES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MIDDLE AGED; PRAVASTATIN; RETROSPECTIVE STUDIES; SIMVASTATIN;

EID: 1042268126     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.121     Document Type: Article

References (32)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
2. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996: 335: 1001-1009.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
4. Matsuzawa Y, Kita T, Mabuchi H, Matsuzaki M, Nakaya N, Oikawa S, et al. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J 2003; 67: 287-294.
5. Mabuchi H, Kita T, Matsuzaki M, Matsuzawa Y, Nakaya N, Oikawa S, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: Secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT). Circ J 2002; 66: 1096-1100.
6. Matsuzaki M, Kita T, Mabuchi H, Matsuzawa Y, Nakaya N, Oikawa S, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J 2002; 66: 1087-1095.
7. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719.
8. Nishikawa H, Miura S, Zhang B, Shimomura H, Arai H, Tsuchiya Y, et al. Pravastatin promotes coronary collateral circulation in patients with coronary artery disease. Coron Artery Dis 2002; 13: 377-381.
9. Radomski MW, Rees DD, Dutra A, Moncada S. S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol 1992; 107: 745-749.
10. Masumoto A, Hirooka Y, Hironaga K, Eshima K, Setoguchi S, Egashira K, et al. Effect of pravastatin on endothelial function in patients with coronary artery disease. Am J Cardiol 2001; 88: 1291-1294.
11. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-1777.
12. Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001; 104: r27-r34.
13. Oi S, Haneda T, Osaki J, Kashiwagi Y, Nakamura Y, Kawabe J, et al. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 1999; 376: 139-148.
14. Luo JD, Zhang WW, Zhang GP, Guan JX, Chen X. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol 1999; 26: 903-908.
15. Hernandez-Perera O, Perez-Sala D, Soria E, Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000; 87: 616-622.
16. Park HJ, Galper JB. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors up-regulate transforming growth factor-beta signaling in cultured heart cells via inhibition of geranylgeranylation of RhoA GTPase. Proc Natl Acad Sci USA 1999; 96: 11525-11530.
17. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998; 83: 490-500.
18. Hasegawa H, Yamamoto R, Takano H, Mizukami M, Asakawa M, Nagai T, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. J Mol Cell Cardiol 2003; 35: 953-960.
19. Saku K, Zhang B, Ohta T, Arakawa K. Quantity and function of high density lipoprotein as an indicator of coronary atherosclerosis. J Am Coll Cardiol 1999; 33: 436-443.
20. Devereux RB. Detection of left ventricular hypertrophy by M-mode echocardiography. Hypertension 1987; 9(Suppl II): II-19-II-26.
21. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-436.
22. Kohara K, Zhao B, Jiang Y, Takata Y, Fukuoka T, Igase M, et al. Relation of left ventricular hypertrophy and geometry to asymptomatic cerebrovascular damage in essential hypertension. Am J Cardiol 1999; 83: 367-370.
23. Luo JD, Xie F, Zhang WW, Ma XD, Guan JX, Chen X. Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes. Br J Pharmacol 2001; 132: 159-164.
24. Sugden PH, Clerk A. 'Stress-responsive' mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ Res 1998; 83: 345-352.
25. Grunler J, Ericsson J, Dallner G. Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochim Biophys Acta 1994; 1212: 259-277.
26. Hori Y, Kikuchi A, Isomura M, Katayama M, Miura Y, Fujioka H, et al. Post-translational modifications of the C-terminal region of the rho protein are important for its interaction with membranes and the stimulatory and inhibitory GDP/GTP exchange proteins. Oncogene 1991: 6: 515-522.
27. Meadows KN, Bryant P, Pumiglia K. Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem 2001; 276: 49289-49298.
28. Palmieri V, Dahlof B, Dequattro V, Sharpe N, Bella JN, de Simone G, et al. Reliability of echocardiographic assessment of left ventricular structure and function: The PRESERVE study (Prospective Randomized Study Evaluating Regression of Ventricular Enlargement). J Am Coll Cardiol 1999; 34: 1625-1632.
29. Ichihara Y, Sugino M, Hattori R, Anno T, Mizuno Y, Yokoi M, et al. Relafion of electrocardiographic left ventricular hypertrophy with and without T-wave changes to systemic blood pressure, body mass, and serum lipids and blood glucose levels in Japanese men. Am J Cardiol 1997; 80: 730-735.
30. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Robbins J, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 281: 1690-1693.
31. Kimpara T, Okabe M, Nishimura H, Hayashi T, Imamura K, Kawamura K. Ultrastructural changes during myocardial hypertrophy and its regression: Long-term effects of nifedipine in adult spontaneously hypertensive rats. Heart Vessels 1997; 12: 143-151.
32. Uehara Y, Hirawa N, Takeda T, Numabe A, Kawabata Y, Nagoshi H, et al. Possible linkage between renal injury and cardiac remodeling in Dahl salt-sensitive rats treated with the calcium channel antagonist benidipine. Hypertens Res 1995; 18: 245-253.